SCHEMBL6016795

SCHEMBL6016795

Cc1[c]c(N(C)C)nc(Cc2ccc(NC(=O)c3ccc4ccccc4c3)cc2)n1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.52
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
CASP3 P42574 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
DEGS1 O15121 1/20 0.48
KDM4E B2RXH2 1/20 0.47
PTGDR2 Q9Y5Y4 7/20 0.46
GPR27 Q9NS67 1/20 0.44
TBXA2R P21731 1/20 0.43
PTGDR Q13258 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ENPP2 Q13822 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6016865 0.94 NR1H4 (0.56) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL5961347 0.89 NR1H4 (0.51) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL6016986 0.89 NR1H4 (0.51) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL5961309 0.87 NPC1 (0.50) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL6016948 0.84 NR1H4 (0.52) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL5961407 0.82 RAB9A (0.56) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL6886843 0.81 KMT2A (0.49) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL5961335 0.81 NR1H4 (0.48) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL6017005 0.81 RAB9A (0.57) NR1H4KMT2AMEN1NPC1RAB9A
SCHEMBL6016950 0.80 NR1H4 (0.59) NR1H4KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633726-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 Actimis Pharmaceuticals, Inc., (US) 2006-03-15 EP disclosed
WO-2004096777-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO disclosed